AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 211 min read$UTHR

ROTHBLATT MARTINE A sold $5.3M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $553.87 ($546.84–$563.56, $5.26M total) across 17 trades on 2026-10-20 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Oct 21, 2026, 8:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 9:00 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The disclosed sale may prompt short‑term traders to consider a modest sell pressure, while long‑term investors may view it as a neutral liquidity move.

02

Market read

A modest insider sell by the CEO, reported via a primary SEC filing, offers limited trading relevance.

03

What to watch

The 10b5-1 plan indicates pre‑planned execution, reducing the likelihood of insider information concerns.

Relevance 5/10Novelty 4/10Timing: after-hours filing today

Background

Form 4 filings disclose insider transactions; investors monitor them for potential signals about company outlook.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

Chairperson & CEO Martine Rothblatt sold $5.3M of UTHR shares via a 10b5-1 plan, reducing her stake to 324,443 shares.

Expected impact

likely slight pressure as the market prices in the insider sell

Evidence & confidence

A $5.3M sale by the CEO is material enough to attract attention, but the amount is modest relative to market cap, so impact is limited.

Market effects

Sector

Minimal; the sale does not affect the broader biotech sector.

Regional

None; the filing is company‑specific.

Global

Low; no global macro implications.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals.

Key entities

  • person
    Martine Rothblatt

    Chairperson & CEO of United Therapeutics

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min